131Ⅰ治疗青少年Graves病58例临床分析

Analyze of 131Ⅰ therapy on 58 youngsters with Graves' disease

    摘要
  • 摘要:
    目的 研究131Ⅰ治疗青少年Graves病的可行性和安全性。
    方法 回顾性分析58例经131Ⅰ治疗的青少年Graves病患者，分别于131Ⅰ（剂量：148~240.5MBq）治疗前和治疗6个月后，用化学发光免疫法检测血清游离三碘甲腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺激素（TSH）水平及用彩色多普勒超声测量甲状腺大小；随访2~7年，评价疗效。
    结果 治疗6个月后，血清FT3和FT4水平明显降低（t=12.43，t=21.21，P均 < 0.01），TSH水平明显升高（t=10.34，P < 0.01），甲状腺体积明显缩小。58例患者中，治愈31例（53.45%），好转16例（27.59%），无效7例（12.07%），甲减3例（5.17%），复发1例（1.72%）。
    结论 131Ⅰ治疗青少年Graves病安全有效。

     

    Abstract:
    Objective To study the feasibility and curative effect of 131Ⅰ therapy for youngsters with Graves' disease.
    Methods Retrospective analyzed 58 youngsters with Graves' disease, to compare the serum free triiodthyroine (FT3), free thyroxine(FT4)and thyroid-stimulating hormone(TSH)levels with chemiluminescent immunoassay and to measure the thyroid gland size with color Doppler diagnostic apparatus before and after six months of 131Ⅰ(148-240.5 MBq)therapy, then followed up for 2－7 years, and clinical efficacy was evaluated according to the Results.
    Results After 6 months of therapy, the levels of FT3and FT4 were significantly decreased(t=12.43, t=21.21, P < 0.01), the level of TSH was significantly increased(t=10.34, P < 0.01), and thyroid volume was decreased obviously. Of the 58 patients, 31(53.45%) patients were cured, 16(27.59%) were much better than before, and 7(12.1%) were invalid, 3(5.17%)were temporary hypothyroid, 1(1.72%) recrudesced.
    Conclusion 131Ⅰ is an effective therapy which is safe and economical to youngsters with Graves' disease.

     

    • HTML全文
    • 参考文献(7)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回